An update from Nanobiotix ( (NBTX) ) is now available.
On April 30, 2025, Nanobiotix announced the presentation of full results from a completed Phase 1 study evaluating JNJ-1900 (NBTXR3) in pancreatic cancer. The study, conducted by The University of Texas MD Anderson Cancer Center, will be presented at the ESTRO 2025 meeting on May 4, 2025. This development highlights Nanobiotix’s ongoing efforts to expand the use of its novel oncology product, NBTXR3, which is activated by radiotherapy and has potential applications across various solid tumors. The company is also hosting a conference call on May 5, 2025, to discuss these findings further.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s stock score reflects significant financial challenges and a negative valuation outlook, primarily due to operational losses and negative equity. However, strategic partnerships and potential future milestones provide a glimpse of optimism, balancing out some of the financial concerns. The technical analysis presents a neutral to slightly positive outlook, while the earnings call indicates strategic progress, especially with the JNJ collaboration, potentially mitigating some financial risks.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, with a focus on developing nanoparticle-based therapeutic approaches. The company is pioneering disruptive, physics-based treatments for cancer and other major diseases, aiming to expand treatment possibilities. Nanobiotix is listed on Euronext Paris and the Nasdaq Global Select Market, and holds over 25 patents across various nanotechnology platforms.
YTD Price Performance: 10.0%
Average Trading Volume: 10,480
Technical Sentiment Signal: Buy
Current Market Cap: $152.7M
For an in-depth examination of NBTX stock, go to TipRanks’ Stock Analysis page.